As of 2026-03-14, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -1.84. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 188.99 mil USD. CCCC's TTM EBITDA according to its financial statements is -102.53 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.5x - 22.2x | 18.9x |
| Forward P/E multiples | 21.1x - 32.0x | 23.3x |
| Fair Price | (21.51) - (22.70) | (21.55) |
| Upside | -890.9% - -934.4% | -892.4% |
| Date | EV/EBITDA |
| 2026-03-12 | -1.87 |
| 2026-03-11 | -2.10 |
| 2026-03-10 | -2.22 |
| 2026-03-09 | -2.67 |
| 2026-03-06 | -2.15 |
| 2026-03-05 | -2.14 |
| 2026-03-04 | -2.19 |
| 2026-03-03 | -2.06 |
| 2026-03-02 | -2.27 |
| 2026-02-27 | -1.82 |
| 2026-02-26 | -1.90 |
| 2026-02-25 | -1.89 |
| 2026-02-24 | -1.53 |
| 2026-02-23 | -1.45 |
| 2026-02-20 | -1.31 |
| 2026-02-19 | -1.28 |
| 2026-02-18 | -1.08 |
| 2026-02-17 | -1.00 |
| 2026-02-13 | -1.06 |
| 2026-02-12 | -1.00 |
| 2026-02-11 | -1.00 |
| 2026-02-10 | -1.01 |
| 2026-02-09 | -0.95 |
| 2026-02-06 | -0.99 |
| 2026-02-05 | -0.89 |
| 2026-02-04 | -1.06 |
| 2026-02-03 | -1.17 |
| 2026-02-02 | -1.05 |
| 2026-01-30 | -1.07 |
| 2026-01-29 | -1.12 |
| 2026-01-28 | -1.19 |
| 2026-01-27 | -1.30 |
| 2026-01-26 | -1.23 |
| 2026-01-23 | -1.30 |
| 2026-01-22 | -1.33 |
| 2026-01-21 | -1.28 |
| 2026-01-20 | -1.33 |
| 2026-01-16 | -1.38 |
| 2026-01-15 | -1.37 |
| 2026-01-14 | -1.47 |
| 2026-01-13 | -1.46 |
| 2026-01-12 | -1.29 |
| 2026-01-09 | -1.30 |
| 2026-01-08 | -1.34 |
| 2026-01-07 | -1.37 |
| 2026-01-06 | -1.19 |
| 2026-01-05 | -1.19 |
| 2026-01-02 | -1.10 |
| 2025-12-31 | -1.08 |
| 2025-12-30 | -1.12 |